Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer, Blood Cancer, Hematology, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any - 21 |
| Updated: | 4/21/2016 |
| Start Date: | March 2010 |
| End Date: | January 2100 |
Target: Identification for High Risk Childhood AML Based on Genome-Wide Analysis
This pilot research trial studies biomarkers in bone marrow samples from pediatric patients
with high risk acute myeloid leukemia. Studying samples of bone marrow from patients with
cancer in the laboratory may help doctors identify and learn more about biomarkers related
to cancer.
with high risk acute myeloid leukemia. Studying samples of bone marrow from patients with
cancer in the laboratory may help doctors identify and learn more about biomarkers related
to cancer.
PRIMARY OBJECTIVES:
I. To provide a detailed, molecular map of pediatric high risk acute myeloid leukemia (AML).
II. To identify mutations, expression profile, gene copy number, loss of heterozygosity
(LOH) status and genomic methylation patterns in order to identify novel changes associated
with pediatric AML.
III. To generate fibroblast cell lines in order to obtain germline nucleic acids from marrow
specimens from AML patients with induction failure.
IV. To identify genomic alterations contributing to induction failure in childhood AML.
OUTLINE:
Banked bone marrow samples from diagnosis and remission are used to develop a detailed
molecular map of pediatric high-risk acute myeloid leukemia. Analysis includes genome single
nucleotide polymorphism (SNP) genotyping, expression, and methylation profiling.
I. To provide a detailed, molecular map of pediatric high risk acute myeloid leukemia (AML).
II. To identify mutations, expression profile, gene copy number, loss of heterozygosity
(LOH) status and genomic methylation patterns in order to identify novel changes associated
with pediatric AML.
III. To generate fibroblast cell lines in order to obtain germline nucleic acids from marrow
specimens from AML patients with induction failure.
IV. To identify genomic alterations contributing to induction failure in childhood AML.
OUTLINE:
Banked bone marrow samples from diagnosis and remission are used to develop a detailed
molecular map of pediatric high-risk acute myeloid leukemia. Analysis includes genome single
nucleotide polymorphism (SNP) genotyping, expression, and methylation profiling.
Inclusion Criteria:
- Diagnosis of acute myeloid leukemia
- High-risk disease
- Treated on COG-AAML03P1 or COG-AAML0531
- Meets the following criteria:
- Initial remission with no known adverse risk factors
- High quantity and quality of ribonucleic acid (RNA) and deoxyribonucleic acid
(DNA) available
- Highly enriched specimens with >= 50% blast available
We found this trial at
1
site
Monrovia, California 91016
Principal Investigator: Soheil Meshinchi, MD
Phone: 206-667-4077
Click here to add this to my saved trials
